{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:28:48Z","timestamp":1768076928163,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tofacitinib is an oral Janus kinase inhibitor for\u00a0the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and patient-reported outcomes (PROs), in patients with PsA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were pooled from two phase 3 studies (NCT01877668\/NCT01882439) in patients with PsA receiving tofacitinib 5 or 10\u00a0mg twice daily to month (M)6 or placebo to M3. Endpoints were: change from baseline in Leeds Enthesitis Index (LEI) or Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC); proportions of patients with enthesitis, relapsed enthesitis after resolution, de novo enthesitis<jats:italic>,<\/jats:italic> low disease activity (LDA) or remission (minimal disease activity\/very low disease activity; Psoriatic Arthritis Disease Activity Score; Disease Activity Index for Psoriatic Arthritis, and Composite Psoriatic Disease Activity in Psoriatic Arthritis); and PROs (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F] total and arthritis pain Visual Analog Scale scores). Descriptive statistics were generated by visit and treatment. Change from baseline in PROs was evaluated by multivariate linear regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seven hundred ten patients from two studies were included: 479 had LEI\u2009&gt;\u20090; 545 had SPARCC\u2009&gt;\u20090; and 136 had LEI\u2009=\u20090 and SPARCC\u2009=\u20090 at baseline. At baseline, among patients with LEI\u2009&gt;\u20090 or SPARCC\u2009&gt;\u20090, mean LEI and SPARCC across treatments and enthesitis locations\/severities ranged from 1.0\u20134.4 and 1.3\u20139.4, respectively. Across several baseline enthesitis locations\/severities, changes from baseline in LEI and SPARCC up to M3 were greater with tofacitinib (-2.0\u20130.4 and -3.5\u20130.2) vs placebo (-\u200d0.9\u2013\u200d0.4 and -1.5\u20131.1). Enthesitis at M6 was more common in patients with greater baseline enthesitis severity. At M6,\u2009\u2264\u200940% of patients with baseline LEI\u2009&gt;\u20090 or SPARCC\u2009&gt;\u20090 whose enthesitis had resolved by M1\/M3 experienced a relapse, and\u2009&lt;\u200914% of patients with baseline LEI\u2009=\u20090 and SPARCC\u2009=\u20090 had de novo enthesitis. LDA\/remission rates generally increased with tofacitinib over time. Baseline LEI location was significantly associated with change from baseline in arthritis pain score, while baseline SPARCC severity was significantly associated with change from baseline in FACIT-F total and arthritis pain scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tofacitinib treatment resulted in improvements in enthesitis in patients with PsA, regardless of baseline location or severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT01877668;NCT01882439.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03108-5","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:01:56Z","timestamp":1692702116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies"],"prefix":"10.1186","volume":"25","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Bedaiwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Dona\u00a0L.\u00a0Fleishaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"3108_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7:59.","journal-title":"Nat Rev Dis Primers"},{"key":"3108_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35\u201343.","journal-title":"Semin Arthritis Rheum"},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69:1692\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3108_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40744-020-00242-3","volume":"7","author":"AM Orbai","year":"2020","unstructured":"Orbai AM, Birt JA, Holdsworth EA, Booth N, Malatestinic WN, Sprabery AT, et al. Impact of enthesitis on psoriatic arthritis patient-reported outcomes and physician satisfaction with treatment: data from a multinational patient and physician survey. Rheumatol Ther. 2020;7:937\u201348.","journal-title":"Rheumatol Ther"},{"key":"3108_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13075-017-1399-5","volume":"19","author":"A Polachek","year":"2017","unstructured":"Polachek A, Cook R, Chandran V, Gladman D, Eder L. The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Res Ther. 2017;19:189.","journal-title":"Arthritis Res Ther"},{"key":"3108_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"3108_CR7","unstructured":"European Medicines Agency. Xeljanz\u00ae (tofacitinib) 5 mg: summary of product characteristics. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/2500\/smpc\/print. Accessed 20 Apr 2023."},{"key":"3108_CR8","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib) highlights of prescribing information. 2022. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed 20 Apr 2023."},{"key":"3108_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"3108_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"key":"3108_CR11","doi-asserted-by":"publisher","first-page":"E270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D, Kivitz AJ, Mease PJ, Gladman DD, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:E270\u201383.","journal-title":"Lancet Rheumatol"},{"key":"3108_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"3108_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/ard.2007.084244","volume":"68","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68:948\u201353.","journal-title":"Ann Rheum Dis"},{"key":"3108_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3108_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729\u201340.","journal-title":"Arthritis Rheum"},{"key":"3108_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.191117","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Hur P, et al. Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data From the US Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48:367\u201375.","journal-title":"J Rheumatol"},{"key":"3108_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1302\/2058-5241.1.000049","volume":"1","author":"A Vaquero-Picado","year":"2016","unstructured":"Vaquero-Picado A, Barco R, Antuna SA. Lateral epicondylitis of the elbow. EFORT Open Rev. 2016;1:391\u20137.","journal-title":"EFORT Open Rev"},{"key":"3108_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/aje\/kwj325","volume":"164","author":"R Shiri","year":"2006","unstructured":"Shiri R, Viikari-Juntura E, Varonen H, Heliovaara M. Prevalence and determinants of lateral and medial epicondylitis: a population study. Am J Epidemiol. 2006;164:1065\u201374.","journal-title":"Am J Epidemiol"},{"key":"3108_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3899\/jrheum.190169","volume":"47","author":"SZ Aydin","year":"2020","unstructured":"Aydin SZ, Bakirci S, Kasapoglu E, Castillo-Gallego C, Alhussain FA, Ash ZR, et al. The relationship between physical examination and ultrasonography of large entheses of the Achilles tendon and patellar tendon origin. J Rheumatol. 2020;47:1026\u201330.","journal-title":"J Rheumatol"},{"key":"3108_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","volume":"21","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019;21:38.","journal-title":"Arthritis Res Ther"},{"key":"3108_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3899\/jrheum.160387","volume":"44","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH. Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab. J Rheumatol. 2017;44:599\u2013608.","journal-title":"J Rheumatol"},{"key":"3108_CR22","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","volume":"60","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, et al. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford). 2021;60:5337\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"3108_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","volume":"21","author":"LC Coates","year":"2019","unstructured":"Coates LC, Wallman JK, McGonagle D, Schett GA, McInnes IB, Mease PJ, et al. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Res Ther. 2019;21:266.","journal-title":"Arthritis Res Ther"},{"key":"3108_CR24","first-page":"S64","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63:S64-85.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3108_CR25","first-page":"1740","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise\u2013the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740\u20135.","journal-title":"J Rheumatol"},{"key":"3108_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/acr.23693","volume":"71","author":"P Hojgaard","year":"2019","unstructured":"Hojgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-Moller J, Ballegaard C, et al. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study. Arthritis Care Res (Hoboken). 2019;71:798\u2013810.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3108_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.berh.2012.09.004","volume":"26","author":"LC Coates","year":"2012","unstructured":"Coates LC, Hodgson R, Conaghan PG, Freeston JE. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26:805\u201322.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3108_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","volume":"29","author":"PJ Mease","year":"2017","unstructured":"Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017;29:304\u201310.","journal-title":"Curr Opin Rheumatol"},{"key":"3108_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3899\/jrheum.181380","volume":"46","author":"PS Helliwell","year":"2019","unstructured":"Helliwell PS. Assessment of enthesitis in psoriatic arthritis. J Rheumatol. 2019;46:869\u201370.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03108-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T23:41:51Z","timestamp":1700523711000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03108-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03108-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OPAL Broaden and OPAL Beyond were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The study protocols were reviewed and approved by the Institutional Review Boards and\/or an Independent Ethics Committee at each study center, and all patients provided written, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appliable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P. J. Mease has received grant\/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol\u00a0Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, Sun, and UCB; and has been on speakers\u2019 bureaus for AbbVie, Amgen, Bristol\u00a0Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer Inc, and UCB. A-M. Orbai has received grant\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Horizon, Janssen, and\u00a0Novartis; and has received consulting fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer Inc, Sanofi, and UCB. O. FitzGerald has received research grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer Inc, has received consulting fees from Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, and Pfizer Inc, and has been on speakers\u2019 bureaus for AbbVie, Janssen, and Pfizer Inc. M. Bedaiwi has been on speakers\u2019 bureaus for AbbVie and Pfizer Inc. D. L. Fleishaker, R. Mundayat, and P. Young are employees and shareholders of Pfizer Inc. P. S. Helliwell is a consultant for Eli Lilly and has received fees for educational services from Janssen, Novartis, and Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}